Objectives: In spite of the national screening program, evidence is lacking on the health benefits such as decrease in complications and cost of screening of diabetes. Little is known about cost-effectiveness of national diabetes screening program. The purpose of this study is to evaluate cost-effectiveness of the current national screening program of type 2 diabetes in South Korea. MethOds: A Markov model for type 2 diabetes that reflected current national screening program was developed. This model analyzed the effects of screening for the population aged 40 and older with first and second FPG (fasting plasma glucose) tests. Data sources for the model parameters included the National Health and Nutrition Examination Survey data for cohort characteristics, the National Health Insurance claims data (HIRA-NPS) for costs, and published literature for other epidemiology data, treatment effects and utility pertaining to diabetes patients. From a payer's perspective, cost per life-year gained (LYG) and cost per quality-adjusted life-year (QALY) gained from screening compared with no screening were calculated based on lifetime costs and accumulated LYGs and QALYs. One-way sensitivity analyses were carried out. Results: The incremental cost-effectiveness ratio (ICER) was higher than 84 million KRW per LYG and higher than 94 million KRW per QALY. The superior strategy in screening interval was identified as every two year. The results of sensitivity analysis showed that older age, higher participation rates of second FPG test, and higher rates of glucose control could improve cost-effectiveness of diabetes screening. cOnclusiOns: The current national diabetes screening program was not cost-effective considering GDP per capita or willingness-to-pay per QALY. Policies to improve participation rates in second screening test need to be established since higher second screening rate leads to positive impacts on ICER and screening interval. Also, effective diabetes management program for diagnosed patients after screening is required as glucose control is related to ICER improvement.
Objectives: Endometriosis is a gynecological disease that affects the quality of life of women of reproductive age and is costly to treat. The purpose of the review was to determine if early detection of endometriosis reduces the costs and increases the effectiveness of endometriosis treatment. MethOds: We systematically reviewed studies published from 1996 to 2012. We evaluated two interventions (medical & surgical) of endometriosis with two outcomes (reduced costs & increased success/ reduced recurrence time). We compared the outcomes of early (minimal & mild) and late (moderate & severe) stage interventions of endometriosis by summarizing the studies and listing their relative main outcomes. We also assessed the quality of the studies by checking (yes or no) whether they conducted a sensitivity analysis. Results: Seven studies met the inclusion criteria of enrolling patients suffering from endometriosis and reporting costs and effects relating to detection and treatment of early and late stage of endometriosis. Early stage interventions are less costly and more effective but only two studies conducted a sensitivity analysis. cOnclusiOns: The findings indicate that early detection of endometriosis improves the outcomes of endometriosis treatment (both medical and surgical) but there are limitations to these findings. The methodological structure of the studies was not conformed to analytical robustness and therefore affected the quality of results and outcomes reported. This validates the World Endometriosis Research Foundation's recommendation for more high-quality studies on the economic evaluation of endometriosis.
PHS62 CoSt EffECtivEnESS AnAlySiS of Hiv AnD AiDS trEAtMEnt in KEnyA: A CoMPArAtivE StuDy of MbAgAtHi DiStriCt AnD Moi tEACHing AnD rEffErAl HoSPitAlS
Owiti EA The University of Nairobi, Nairobi, Kenya Objectives: HIV and AIDS is a major cause of premature death and impose a large disease burden in Kenya. Antiretroviral treatment (ART) is one of the interventions being implemented to mitigate these impacts. Economic studies on the cost and health effects of ART are very scarce in developing countries, Kenya included. The objectives of this research were to estimate health care utilization, the unit costs of services and the cost per life year (LYs) gained of HIV treatment interventions from a provider's perspective. MethOds: A retrospective study of adults on ART and those not on ART, had CD4 counts 250 and below at enrolment. Data was collected from Mbagathi District Hospital (Mbagathi) (n= 350) and Moi Teaching and Referral Hospital (Moi) in Kenya (n= 400). A micro-costing method was used to cost all the treatment inputs and Markov modelling estimated the cost-effectiveness analysis, lifetime costs and health benefits of HIV treatments in the two hospitals. Results: The undiscounted lifetime costs for No-ART in Mbagathi and Moi were, KSh169,123 ($2,260) and KSh184,415 ($2,464) respectively, while life years gained for both hospitals was 2.68 years. The undiscounted lifetime costs for the ART group in Mbagathi and Moi were KSh932,071 ($1,245) and KSh1, 608, 496 ($21, 490) Objectives: Multiple Sclerosis (MS) disease treatment requires high adherence levels to maximize medicine effectiveness. It has been shown that comprehensive care at home programs in MS improve treatment adherence. In Mexico, average adherence levels for MS is less than 80%, therefore, the purpose of this study was to evaluate a comprehensive care at home program in patients of the Mexican Institute of Social Security with Multiple Sclerosis aimed to improve treatment adherence and to increase life expectancy. MethOds: The study design was a costeffectiveness analysis from the governmental perspective. The costs for patient care were obtained from the Diagnosis-related groups that Mexican Institute of Social Security publishes and drugs costs were obtained also from the Institute. Costs were expressed in 2013 constant USD. A Markov model with sixty monthly cycles was developed. Based on the Expanded Disability Status Scale, we divided the model into six possible stages (4 EDSS stages, 2 for relapses according to EDSS stage) and death. We analyzed six different medicines (intramuscular interferon beta 1a, subcutaneous interferon beta 1a, subcutaneous interferon beta 1b, glatiramer acetate, Natalizumab and Fingolimod. Parameters were obtained from MS literature in Mexico. ICER per year life gained was estimated and discounted at 5% annual rate. Results: The comprehensive care at home program increases life expectancy in a range of 6 to 12 months depending on the medicine we were analyzing. ICER is cost-effective ($ 556) in a five-year horizon. The program could increase adherence in more than 20 percentage points in the best scenario. cOnclusiOns:
The comprehensive care at home program could improve patient's health and quality of life through increasing treatment adherence, therefore it could be considered for implementation beyond the Mexican institute of Social Security. Objectives: Hospital care at home programs could improve patient's health and also reduce health system costs. In Mexico, there are few programs that offer this service. The purpose of this study was to analyze a hospital care at home program in patients of the Mexican Institute of Social Security in Mexico City aimed to avoid nosocomial infections and hospital readmissions. MethOds: The study design was a cost-effectiveness analysis from the governmental perspective. We considered 540 potential patients. Through a decision tree model two scenarios were compared: 1. Inpatient Hospital Care vs. 2. Hospital care at home. First scenario costs were: hospitalization (per day) and nosocomial infection. Second scenario cost considered was hospital at home care (per day). Both scenarios considered hospital readmission costs. All the costs were obtained from the Mexican Institute of Social Security and were expressed in 2013 constant USD. Effectiveness parameters were obtained from similar programs in Mexico and Spain. As effectiveness measures we considered: nosocomial infection avoided, hospital readmission avoided and death avoided in a one-year horizon. Univariate sensitivity analysis for costs was performed. We estimated the hospital supply extension through bed days avoided. Also budget impact analysis was conducted. Results: Hospital care at home program reduces 21% nosocomial infection, 48% hospital readmission and 5% deaths. The program is very cost-effective for nosocomial infection avoided (ICER = $2,435), cost-saver for hospital readmission (ICER = $ -1,674) and cost-effective for death avoided (ICER = $ 15,223). Hospital supply extension is 1,620 beds per year. Budget impact analysis showed that nephroprotection could generate savings of 25% depending on the Hospital at home care cost per day. cOnclusiOns: Hospital care at home improve patient's Health, reduces health system costs and expands hospital supply, therefore, it could be considered for implementation in our country.
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CoSt-EfECtivEnESS AnAlySiS of inSulin glArginE (lAntuS) initiAtion by PHArMACiStS in A CAnADiAn SEtting: tHE rxing StuDy
Al Hamarneh Y. 1 , Sauriol L. 2 , Tsuyuki R. 1 , Brown S. T. 3 1 University of Alberta, Edmonton, AB, Canada, 2 Sanofi, Laval, QC, Canada, 3 Ethicon, Inc, Somerville, NJ, USA Objectives: Type 2 diabetes is a progressive disease with 50% loss in insulinproducing capacity at time of diagnosis, with an average 5% annual thereafter. Therefore, many patients with type 2 diabetes (T2DM) require insulin treatment. Pharmacists are frontline health care professionals who see patients with T2DM frequently and as such they could help them achieve their targets by intervening in timely manner. The RxING study assessed the effect of a community pharmacist intervention in uncontrolled patients with T2DM treateted with oral hypoglycemic agents. Those patients were prescribed insulin glargine and followed up for 26 weeks by their pharmacist. At endpoint, the average A 1c reduction was 1.8% (95%CI 1.4 to 2). The objective was to assess the cost-effectiveness of having pharmacists' early intervention in prescribing insulin. MethOds: The IMS CORE Diabetes Model, a Markov structure and Monte Carlo simulation model was used to assess complications and disutilities. Health utility and cost data were obtained from recently published Canadian publications. The efficacy of insulin in terms of HbA 1c reduction, and corresponding rates of hypoglycemia were obtained from the RxING study. The base case analyses examined the effects of having pharmacist prescribe insulin 1, 2 and 3 years earlier than a physician. Results: Having pharmacists prescribe insulin 1 year earlier than a physician resulted in an incremental cost savings of $790 (CDN$) and a gain of 0.048 QALYs per patient. Early pharmacist prescription of insulin by 2 years resulted in an increment cost savings of $687 (CDN$) and a gain of 0.075 QALYs per year. At 3 years earlier the results were a cost savings of $105 and a gain of 0.086 QALYs. cOnclusiOns: Having pharmacists initiate insulin sooner in uncontrolled T2DM results in cost-savings and delays the development of
